Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

Authors of a recent review explored the complex relationship between CKD, COVID-19, and anemia and offered practice points based on clinical experience. Patients with chronic kidney disease (CKD) ...

Source: Getty Images Addressing anemia in CKD requires a proactive, multifaceted approach, incorporating both conventional and nutritional strategies. Early recognition and intervention are essential ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be a better adjunct treatment to reduce anemia risk than glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes ...

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease. Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

The FDA approved vadadustat (Vafseo) for chronic kidney disease (CKD)-related anemia in adults who have been on dialysis for at least 3 months, developer Akebia Therapeutics announced on Wednesday.

Treatment with vadadustat was noninferior to darbepoetin alfa in correcting and maintaining Hb levels in adults with incident dialysis-dependent CKD. The Food and Drug Administration (FDA) has ...

We observed that anemia and chronic kidney disease are two frequent conditions among stroke patients. Anemia was independently associated with a decreased one-year survival. Although GFR was ...

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment ...